Abstract: Objective To investigate the effect of coronary heart disease (CHD) on the development and prognosis of corona virus disease 2019 (COVID-19) patients. Methods Eighty cases of COVID-19 cured and discharged from our hospital were analyzed retrospectively, including 58 cases of common type, 14 cases of severe type and 8 cases of critical type. The patients were divided into two groups: 36 patients with CHD and 44 patients without CHD. The general data including age, sex, body mass index, blood oxygen saturation, heart rate, blood pressure, days of hospitalization, days needed for obvious improvement of pulmonary CT, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) medication and disease classification were compared between the two groups. The test results including white blood cell count (WBC), lymphocyte count (LYM), C-reactive protein (CRP), liver and kidney function were also compared between the two groups. Results Compared with the patients without CHD, the patients with CHD showed lower blood oxygen saturation, faster heart rate, longer hospital stay, longer days for improvement of chest CT and higher proportion of patients taking ACEI/ARB drugs (all P＜0.05). The levels of WBC and LYM were significantly lower in the patients with CHD than those without CHD, while the level of CRP was higher (P＜ 0.05). The proportion of severe and critical patients with CHD was significantly higher than that of patients without CHD, and the proportion of severe and critical patients with COVID-19 taking ACEI/ARB drugs was higher than that of patients without taking drugs (P＜0.05). Conclusion The condition of COVID-19 patients with CHD is more serious. ACEI/ARB drugs may aggravate the condition of patients with COVID-19.

Key words: pneumonia, viral, coronary disease, patient acuity, prognosis, angiotensin-converting enzyme inhibitors; angiotensin receptor antagonists, COVID-19, ACE2